No Data
No Data
Buy Rating Affirmed for Scynexis on Robust Financials and Promising Antifungal Pipeline
Analysts' Top Healthcare Picks: Cormedix (CRMD), SCYNEXIS (SCYX)
Buy Recommendation: Scynexis's Ibrexafungerp Promises Market Breakthrough and Financial Growth
Express News | SCYNEXIS Q1 2024 GAAP EPS $0.01 Beats $(0.20) Estimate, Sales $1.400M Beat $303.000K Estimate
Express News | Scynexis : Ended Q1 2024 With Cash, Cash Equivalents & Investments of $94.2 Mln & Projects Cash Runway of More Than Two Years
Earnings Flash (SCYX) SCYNEXIS Reports Q1 Revenue $1.4M
04:51 PM EDT, 05/08/2024 (MT Newswires) -- Earnings Flash (SCYX) SCYNEXIS Reports Q1 Revenue $1.4M
No Data